This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Anatabloc(R) Unflavored (Photo: Business Wire)

Rock Creek Pharmaceuticals, Inc., a wholly owned subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), announced that Anatabloc ® Unflavored is available as an option on the shopping cart on the Anatabloc ® website at as of today. Anatabloc ® Unflavored is a revised formulation containing the same active dietary ingredients in the same dose as our original Anatabloc ® product. A significant number of individuals using Anatabloc ® communicated to us their interest in an Anatabloc ® product without mint flavoring; others expressed an interest in a product that does not contain artificial sugar substitutes. Anatabloc ® Unflavored is a formulation that can be used by any current or new users of our Anatabloc ® product who wish to avoid sweeteners and flavors. The new formulation is the same as the original with respect to the other ingredients and can be used in the same manner.
Anatabloc(R) Unflavored (Photo: Business Wire)

Anatabloc(R) Unflavored (Photo: Business Wire)

As of today, the Anatabloc ® Unflavored image appears on the main landing page for the Anatabloc ® website. Visitors to the website will be able to purchase Anatabloc ® Unflavored at a single, one-time purchase price of $99.99 or as part of our Advantage Club renewal program, at $79.99. Each bottle of Anatabloc ® Unflavored will contain 200 tablets.

Curtis Wright, IV, MD/MPH, Senior Vice President and Medical Director of Rock Creek Pharmaceuticals said, “When we received the first request for an alternative formulation, there was never any doubt that we would try to fulfill it, since we anticipated that various consumers would want to have the benefit of using Anatabloc ® without artificial flavors or sweeteners. We are very pleased that our production team was able to develop a formulation free of artificial flavors and sweeteners for those customers who either do not care for the mint flavoring or prefer not to use artificial sweeteners for a variety of personal reasons. Our goal in formulating Anatabloc ® is to promote health and optimum nutrition, and removing barriers to use for any customer is always a good thing to do. Most people prefer the original formulation, but now Anatabloc ® users have another choice.”

Jonnie R. Williams, CEO of Rock Creek’s parent company, Star Scientific, Inc., stated, “The brand extension of Anatabloc ® Unflavored tablets at this time underscores our commitment to be responsive to consumer demands as well as drive consumer acceptance.”

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs